Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 15:13:100475.
doi: 10.1016/j.ajpc.2023.100475. eCollection 2023 Mar.

Management of hypertension in obstructive sleep apnea

Affiliations
Review

Management of hypertension in obstructive sleep apnea

Yi-Hui Ou et al. Am J Prev Cardiol. .

Abstract

Obstructive sleep apnea (OSA) plays an important role in the development of hypertension. Thus, this review summarizes pharmacological and non-pharmacological approaches to blood pressure (BP) control in patients with OSA. Current treatments for OSA, such as continuous positive airway pressure, are effective at lowering BP. However, they only provide a modest BP reduction, and pharmacological treatment remains important for achieving optimal BP control. Furthermore, current guidelines for the treatment of hypertension do not make specific recommendations on pharmacological treatment protocols for controlling BP in patients with OSA. Moreover, the BP-lowering effects of various classes of antihypertensives may be different in hypertensive patients with OSA than in those without OSA due to the underlying mechanisms that promote hypertension in OSA. The acute and chronic increase in sympathetic nerve activity in patients with OSA explain the effectiveness of beta blockers in controlling BP in these patients. As activation of the renin-angiotensin-aldosterone system may also promote hypertension in OSA, angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers have generally been found effective for lowering BP in hypertensive patients with OSA. The aldosterone antagonist spironolactone also produces a good antihypertensive response in patients with OSA and resistant hypertension. However, there are limited data available that compare the effects of various classes of antihypertensive medication on BP control in those with OSA, and most data have been obtained from small-scale studies. This demonstrates the need for large-scale randomized controlled trials to evaluate a range of BP-lowering regimens in patients with OSA and hypertension.

Keywords: AHI, apnea hypopnea index; Antihypertensives; Apnea Hypopnea Index; BP, blood pressure; Blood pressure; CPAP, continuous positive airway pressure; Continuous positive airway pressure; Hypertension; MAD, mandibular advancement device; OSA, obstructive sleep apnea; Sleep apnea.

PubMed Disclaimer

Conflict of interest statement

None declared for all the authors.

Figures

Image, graphical abstract
Graphical abstract
Fig 1
Fig. 1
Different strategies of blood pressure control in patients with hypertension and obstructive sleep apnea. Abbreviations: MAD, mandibular advancement device; CPAP, continuous positive airway pressure.
Fig 2
Fig. 2
Landmarks of continuous positive airway pressure and mandibular advancement device for obstructive sleep apnea. Abbreviations: MAD, mandibular advancement device; CPAP, continuous positive airway pressure; OSA, obstructive sleep apnea; AASM, American academy of sleep medicine; SAVE, the Sleep Apnea Cardiovascular Endpoints.

Similar articles

Cited by

References

    1. NCD Risk Factor Collaboration (NCD-RisC) Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957–980. - PMC - PubMed
    1. Forouzanfar M.H., et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115mm Hg, 1990-2015. JAMA. 2017;317(2):165–182. - PubMed
    1. Roth G.A., et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–3021. - PMC - PubMed
    1. Williams B., et al. ESC/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of cardiology and the European society of hypertension. J Hypertens. 2018;36(10):1953–2041. - PubMed
    1. Ettehad D., et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957–967. - PubMed